Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4731891 | 0.98 | HDAC4 (0.37) | HDAC4TSHRCYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL15232657 | 0.92 | — | — | |
| SCHEMBL15062781 | 0.80 | ALDH1A1 (0.39) | HDAC4TSHRCYP2C19ALDH1A1SMN1; SMN2 | |
| SCHEMBL14949533 | 0.79 | TSHR (0.32) | HDAC4TSHRCYP2C19 | |
| SCHEMBL21242398 | 0.78 | HTT (0.40) | TSHRCYP2C19ALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL782010 | 0.76 | KDM4E (0.41) | TSHRCYP1A2 | |
| SCHEMBL27525129 | 0.75 | TSHR (0.32) | TSHRCYP2C19ALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL2480644 | 0.75 | NPSR1 (0.36) | TSHRCYP2C19ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL9698835 | 0.73 | ADRB2 (0.54) | CYP2C19ALDH1A1SMN1; SMN2LMNABLM | |
| SCHEMBL22302657 | 0.73 | ALDH1A1 (0.32) | TSHRCYP2C19ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021065980-A1 | BET DEGRADER | 協和キリン株式会社 | 2021-04-08 | — | — | WO | disclosed |
| EP-3504213-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | ArQule, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| US-20180319772-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-11-08 | — | — | US | disclosed |
| US-10106526-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| WO-2018039310-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-06-29 | — | — | US | disclosed |
| EP-2518080-B1 | Antibiotic peptides | AMP THERAPEUTICS GMBH (DE) | 2016-05-18 | — | — | EP | disclosed |
| EP-2782580-A1 | SELECTIVE KINASE INHIBITORS | Portola Pharmaceuticals, Inc. (US) | 2014-10-01 | — | — | EP | disclosed |
| CN-101801995-B | Antibacterial peptide | AMP THERAPEUTICS GMBH & CO KG | 2013-10-30 | — | — | CN | disclosed |
| EP-2170928-B1 | ANTIBIOTIC PEPTIDES | AMP THERAPEUTICS GMBH (DE) | 2013-07-03 | — | — | EP | disclosed |
| EP-2597955-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-06-05 | — | — | EP | disclosed |
| WO-2013078468-A1 | SELECTIVE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | WO | disclosed |
| WO-2012016082-A1 | QUINOLINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-02-02 | — | — | WO | disclosed |
| EP-2411387-A2 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | Pathway Therapeutics, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010110685-A2 | PYRIMDDINYL AND 1,3,5-TRIAZINYL BENZIMTOAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | WO | disclosed |
| CN-101801995-A | Antibacterial peptide | AMP THERAPEUTICS GMBH & CO KG | 2010-08-11 | — | — | CN | disclosed |
| WO-2008094909-A2 | QUINAZOLINONE AND FUSED PYRIMIDINONE COMPOUNDS AND THEIR USE IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-07 | — | — | WO | disclosed |
| EP-0067518-B1 | MODIFIED BETA-LACTAM COMPOUNDS | BEECHAM GROUP PLC (GB) | 1985-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106526-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | HDAC4 757/4885TSHR 3200/4885CYP2C19 2330/4885 |
| US-20180319772-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | HDAC4 757/4885TSHR 3200/4885CYP2C19 2330/4885 |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | HDAC4 757/4885TSHR 3200/4885CYP2C19 2330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.